FindTrial
Sign In

Sodium-glucose co-transporter 2 inhibitors in acute heart failure

Effect of sodium-glucose co-transporter 2 (SGLT-2) inhibitors on blood lactate and cardiovascular outcomes in patients of acute decompensated heart failure- A prospective observational study - SGLTAHF

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/02/081420
Enrollment
130
Registered
2025-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I502- Systolic (congestive) heart failure

Interventions

None listed

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients 18 years of age and above and diagnosed with acute decompensated heart failure (ADHF)

Exclusion criteria

Exclusion criteria: Patients of heart failure with a recent history of serious cardiovascular event such as myocardial infarction, stroke, or other thromboembolic events in the last month. Patients of heart failure with sepsis. Patients with Creatinine Clearance less than 30 mL per min or those requiring dialysis. Patients with a history of diabetic ketoacidosis. Patients who refuse to participate.

Design outcomes

Primary

MeasureTime frame
Change in the serum levels of lactate at Day 7 compared to baseline in patients of ADHF after starting SGLT-2 inhibitorsTimepoint: Day 7, day 30—

Secondary

MeasureTime frame
Change in dyspnoea score Change in NYHA severity Change in urinary output Change in BNP or NT-Pro BNP Cardiovascular outcomes Adverse events Timepoint: Day 7, Day 30, Day 60—

Countries

India

Contacts

Public ContactUpinder Kaur

Institute of Medical Sciences, BHU

drupinder.bhu@gmail.com9935615546

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026